SLC27A2 Antibody

What is SLC27A2 and why is it significant in biomedical research?

SLC27A2, also known as FATP2 (fatty acid transport protein 2), is a critical protein involved in long-chain fatty acid uptake and transport into cells. It plays an essential role in lipid metabolism, energy storage, and lipid droplet formation within cellular systems. The significance of SLC27A2 in research has expanded considerably as dysregulation of this protein has been implicated in several metabolic disorders, including obesity, diabetes, and fatty liver disease . More recently, SLC27A2 has emerged as a potential immune biomarker for hematological malignancies, including diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML) . This dual role in both metabolic processes and immune regulation makes SLC27A2 a compelling target for researchers investigating the intersection of metabolism and immunity in disease pathogenesis.

What types of SLC27A2 antibodies are currently available and how do they differ in research applications?

Several types of SLC27A2 antibodies are available for research applications, each with distinct characteristics:

• Polyclonal antibodies: These include rabbit polyclonal antibodies like CAB1077, which recognize multiple epitopes of the SLC27A2 protein, providing high sensitivity but potentially lower specificity . These antibodies often demonstrate reactivity across species, including human, mouse, and rat samples.

• Monoclonal antibodies: These are more specific to particular epitopes within the SLC27A2 protein, offering higher specificity for particular applications.

• Conjugated antibodies: Examples include the Alexa Fluor 750-conjugated anti-SLC27A2 antibodies, which are particularly useful for immunofluorescence applications, allowing direct visualization without secondary antibody requirements .

• Region-specific antibodies: Some antibodies target specific regions of the SLC27A2 protein, such as N-terminal specific antibodies (ABIN2781594) or those targeting amino acids 401-500 or 346-405, which may be advantageous for studies examining particular domains of the protein.

The selection of the appropriate antibody depends on the specific research question, application method, and target species. For detailed epitope mapping studies, region-specific antibodies may be preferred, while polyclonal antibodies often provide greater sensitivity in applications like Western blotting.

What is the cross-species reactivity profile of SLC27A2 antibodies, and how should researchers account for this in experimental design?

SLC27A2 antibodies demonstrate varying degrees of cross-species reactivity, which is crucial to consider when designing experiments. Based on the search results, the following reactivity profiles have been documented:

When designing experiments using these antibodies, researchers should:

• Validate the antibody in their specific model organism before proceeding with full experiments

• Consider sequence homology between species when interpreting cross-reactivity data

• Include appropriate positive controls from validated species

• Be aware that predicted reactivity percentages (like those listed for ABIN2781594) represent sequence homology and may not directly correlate with actual binding efficiency

For studies comparing SLC27A2 across species, selecting antibodies with documented reactivity in all target species is essential to ensure comparable results .

What are the validated applications for SLC27A2 antibodies and how should protocols be optimized?

SLC27A2 antibodies have been validated for multiple applications, each requiring specific optimization approaches:

• Western Blotting (WB): All three antibodies in the search results have been validated for WB applications . For optimal results:

  • Use cell lysates as positive controls, as validated during antibody characterization

  • Consider using reduced loading buffer conditions

  • Optimize primary antibody concentration (typically 1:500 to 1:2000 dilution)

  • Include appropriate blocking steps to minimize non-specific binding

• Immunohistochemistry (IHC): For tissue-based detection of SLC27A2:

  • Antigen retrieval methods should be optimized for the specific tissue type

  • Both the N-terminal antibody (ABIN2781594) and the Alexa Fluor 750-conjugated antibody have been validated for IHC applications

  • Consider tissue-specific controls, particularly when examining different metabolic tissues

• Immunofluorescence (IF): The Alexa Fluor 750-conjugated antibody is particularly suited for this application , allowing:

  • Direct visualization without secondary antibody

  • Compatibility with multi-color imaging studies

  • Reduced background compared to indirect methods

• ELISA: While not explicitly mentioned for all antibodies, some SLC27A2 antibodies can be used in ELISA applications, requiring:

  • Careful optimization of antibody concentration

  • Selection of appropriate coating and blocking buffers

  • Validation of specificity using recombinant SLC27A2 protein

Protocols should be optimized based on the specific antibody used, the experimental question, and the target tissue or cell type under investigation.

How should researchers approach SLC27A2 antibody validation for studying hematological tumors?

Given the emerging role of SLC27A2 as a biomarker in hematological tumors, proper antibody validation in this context is critical. Based on the recent findings regarding SLC27A2 in DLBCL and AML , researchers should:

• Perform comprehensive specificity testing:

  • Use positive controls from cell lines with known SLC27A2 expression (particularly hematological cell lines)

  • Include SLC27A2 knockout or knockdown samples as negative controls

  • Validate antibody performance in both normal and malignant hematopoietic cells

• Establish expression patterns:

  • Compare antibody staining patterns with RNA expression data from the same samples

  • Verify localization patterns align with expected cellular distribution

  • Document any differences in expression between DLBCL and AML samples, as the research indicates opposite roles of SLC27A2 in these malignancies

• Optimize for immune cell populations:

  • Given the documented correlations between SLC27A2 and immune cell infiltration, validate antibody performance in:

    • T cell populations (both CD4+ and CD8+)

    • B cells

    • Macrophages

    • NK cells

  • Consider the microenvironmental context when interpreting staining results

• Functional validation:

  • Confirm antibody utility in detecting changes following SLC27A2 knockdown, as demonstrated in recent cell cycle and apoptosis studies in DLBCL cells

  • Correlate protein detection with functional readouts of fatty acid metabolism

These validation steps are essential given the significant but opposing correlations between SLC27A2 expression and immune cell infiltration in DLBCL versus AML .

What controls should be included when using SLC27A2 antibodies in experimental protocols?

Proper controls are critical for generating reliable and interpretable data with SLC27A2 antibodies:

• Positive Controls:

  • Cell lysates with confirmed SLC27A2 expression (as specified in the antibody validation data)

  • Tissues with known high expression (liver and kidney typically express SLC27A2 at high levels)

  • Recombinant SLC27A2 protein (particularly useful for testing antibody specificity)

• Negative Controls:

  • SLC27A2 knockout or knockdown samples

  • Secondary antibody-only controls to assess non-specific binding

  • Isotype controls (particularly important for flow cytometry applications)

  • Peptide competition assays using the immunizing peptide

• Specificity Controls:

  • Testing for cross-reactivity with other SLC27 family members, particularly SLC27A1 (FATP1) and SLC27A4 (FATP4), which share sequence homology

  • Including samples from multiple species if performing cross-species comparisons

• Procedural Controls:

  • For IF/IHC: Include tissue sections known to be negative for SLC27A2

  • For WB: Include molecular weight markers to confirm the expected band size (approximately 70 kDa for human SLC27A2)

  • For quantitative applications: Include gradient dilutions to ensure linearity of signal

These controls are particularly important when investigating SLC27A2 in novel contexts, such as its recently described role in hematological tumors .

How can SLC27A2 antibodies be utilized to investigate the relationship between fatty acid metabolism and immune function in hematological malignancies?

Recent research has revealed intricate connections between SLC27A2-mediated fatty acid metabolism and immune regulation in hematological tumors . To investigate these relationships, researchers can employ SLC27A2 antibodies in several sophisticated approaches:

• Dual immunofluorescence staining:

  • Use conjugated SLC27A2 antibodies alongside immune cell markers to directly visualize spatial relationships between SLC27A2-expressing cells and immune infiltrates

  • Apply this technique to tissue microarrays of DLBCL and AML samples to quantify co-localization patterns

• Flow cytometry-based approaches:

  • Combine SLC27A2 antibody staining with immune subset markers to quantify expression levels across different immune populations

  • Sort SLC27A2-high and SLC27A2-low populations for further functional analysis

• Immunoprecipitation followed by mass spectrometry:

  • Use SLC27A2 antibodies to pull down protein complexes to identify binding partners in immune cells

  • Compare interaction networks between normal and malignant hematopoietic cells

• Chromatin immunoprecipitation (ChIP) studies:

  • Investigate transcriptional regulation of SLC27A2 in immune cells under different metabolic conditions

  • Identify potential transcription factors connecting immune signaling to SLC27A2 expression

Recent findings show striking differences in the correlation patterns between SLC27A2 and immune cells in DLBCL versus AML. In DLBCL, SLC27A2 expression positively correlates with T cell (CD4+ and CD8+), endothelial cell, macrophage, and NK cell infiltration, while in AML, SLC27A2 negatively correlates with B cells, CD8+ T cells, and macrophages . These opposing relationships suggest context-specific roles that warrant detailed investigation using the approaches outlined above.

What are the methodological approaches for studying SLC27A2's impact on cell cycle and apoptosis in cancer cells?

Based on recent findings demonstrating SLC27A2's involvement in cell cycle regulation and apoptosis in DLBCL cells , researchers can employ the following methodological approaches:

• siRNA-mediated knockdown experiments:

  • Following the validated approach where SLC27A2 siRNA-817 showed significant interference effects, researchers should:

    • Design multiple siRNAs targeting different regions of SLC27A2 mRNA

    • Validate knockdown efficiency using both qPCR and Western blot with SLC27A2 antibodies

    • Include non-targeting siRNA controls

• Cell cycle analysis:

  • Flow cytometry with propidium iodide staining to quantify cell distribution across G1, S, and G2/M phases

  • EdU incorporation assays to directly measure DNA synthesis

  • Western blot analysis of cell cycle proteins (cyclins, CDKs) following SLC27A2 modulation

  • Immunofluorescence using SLC27A2 antibodies to visualize subcellular localization during different cell cycle phases

• Apoptosis assays:

  • Annexin V/PI staining to quantify early and late apoptotic populations

  • Caspase activation assays (particularly caspase-3/7)

  • TUNEL assay for DNA fragmentation

  • Western blot analysis of apoptotic markers (cleaved PARP, BAX/BCL-2 ratio)

• Rescue experiments:

  • Re-expression of SLC27A2 in knockdown cells to confirm specificity

  • Introduction of fatty acid metabolism intermediates to determine whether SLC27A2's effects are dependent on its enzymatic activity

Recent experimental data showed that low expression of SLC27A2 (via siRNA-817) significantly promoted DLBCL cell cycle progression (decreased G1 phase, increased S and G2 phases) and inhibited apoptosis . These findings suggest that SLC27A2 normally functions as a tumor suppressor in DLBCL, making it a valuable target for therapeutic development.

How can researchers effectively study the opposing roles of SLC27A2 in different hematological malignancies?

The discovery that SLC27A2 exhibits opposing relationships with prognosis and immune infiltration in DLBCL versus AML presents a fascinating research challenge. To effectively investigate these divergent roles, researchers should consider:

• Comparative multi-omics approaches:

  • Parallel proteomics analysis of SLC27A2 interaction networks in both malignancies

  • Metabolomics profiling to identify differences in fatty acid metabolism pathways

  • Transcriptomics to identify divergent downstream effects of SLC27A2 expression

  • Single-cell approaches to resolve cell-type specific effects

• Microenvironmental context studies:

  • Co-culture systems with immune cells relevant to each malignancy

  • 3D organoid models incorporating stromal and immune components

  • Spatial transcriptomics to map SLC27A2 expression in relation to immune niches

• Pathway analysis:

  • Phosphoproteomics to identify differential signaling pathways activated by SLC27A2

  • Inhibitor studies targeting fatty acid metabolism in both malignancies

  • Gene set enrichment analysis as demonstrated in the recent study , which showed that:

    • In DLBCL, high SLC27A2 expression correlates with fatty acid pathways, immune pathways, and cell cycle regulation

    • In AML, low SLC27A2 expression primarily affects immune pathways

• Biomarker validation studies:

  • Develop standardized IHC protocols using validated SLC27A2 antibodies

  • Establish scoring systems for SLC27A2 expression in clinical samples

  • Correlate with treatment response data in both malignancies

The finding that SLC27A2 functions as a protective factor in DLBCL but appears to have opposite effects in AML highlights the context-dependent nature of metabolic regulators in cancer. This complexity necessitates careful experimental design with appropriate controls and validation across multiple patient cohorts .

What are common challenges when detecting SLC27A2 in different tissue and cell types, and how can they be addressed?

Researchers frequently encounter several challenges when detecting SLC27A2 across different experimental systems:

• Variability in expression levels:

  • Challenge: SLC27A2 expression can vary dramatically between tissue types and disease states

  • Solution: Optimize antibody dilutions for each tissue type; use more sensitive detection methods (such as amplification systems) for low-expressing tissues

• Cross-reactivity with other FATP family members:

  • Challenge: The SLC27 family includes multiple members with sequence homology

  • Solution: Select antibodies targeting unique epitopes of SLC27A2; validate specificity using overexpression and knockdown controls; consider performing parallel IHC and RNA analysis (ISH or qPCR)

• Subcellular localization challenges:

  • Challenge: SLC27A2 can localize to multiple cellular compartments (plasma membrane, peroxisomes, endoplasmic reticulum) depending on cellular state

  • Solution: Use subcellular fractionation followed by Western blotting; perform co-localization studies with organelle markers; optimize fixation protocols to preserve relevant cellular structures

• Background staining in IHC/IF applications:

  • Challenge: High lipid content tissues often exhibit high background

  • Solution: Optimize blocking protocols (BSA, normal serum, commercially available blockers); consider antigen retrieval optimization; use conjugated antibodies like the Alexa Fluor 750 version to reduce secondary antibody background

• Inconsistent results between detection methods:

  • Challenge: Results from WB, IHC, and IF sometimes differ for the same samples

  • Solution: Use multiple antibodies targeting different epitopes; validate with genetic approaches (siRNA); consider native vs. denatured protein detection differences

For hematological samples specifically, optimizing fixation protocols is particularly important, as demonstrated in recent studies of SLC27A2 in DLBCL and AML samples .

How should researchers interpret seemingly contradictory results in SLC27A2 expression studies?

When faced with contradictory results regarding SLC27A2 expression or function, researchers should consider several potential explanations and follow a systematic approach:

• Biological context differences:

  • The recent finding that SLC27A2 has opposing relationships with immune infiltration in DLBCL versus AML demonstrates that biological context profoundly influences its function

  • Consider cell-type specific regulatory mechanisms when comparing results across different systems

  • Examine the metabolic state of the system (fed vs. fasted, glycolytic vs. oxidative)

• Methodological considerations:

  • Antibody epitope accessibility may differ between applications (WB vs. IHC)

  • Different antibodies may recognize distinct isoforms or post-translationally modified forms

  • Sample preparation methods can affect detection (protein extraction protocols, fixation methods)

• Analytical approach:

  • When faced with contradictory results:

    • First verify technical reproducibility within each system

    • Compare RNA and protein expression patterns

    • Validate with functional approaches (genetic manipulation)

    • Consider spatial and temporal dynamics

• Data interpretation framework:

  • Context-specific expression patterns may reflect biological reality rather than experimental error

  • The recent study demonstrating opposite prognostic implications of SLC27A2 in DLBCL versus AML provides a prime example of how the same molecule can have context-dependent functions

  • Consider creating an integrated model that accounts for different regulatory mechanisms across cell types

• Validation across multiple datasets:

  • Use publicly available data (TCGA, GTEx) to verify expression patterns

  • The recent study validated SLC27A2 expression patterns across GSE30029, TCGA-LAML, TCGA-DLBCL and GTEx datasets

This systematic approach can help distinguish meaningful biological complexity from technical artifacts.

What considerations are important when quantifying SLC27A2 expression for biomarker development?

As SLC27A2 emerges as a potential biomarker for hematological malignancies , researchers should consider several critical factors for accurate quantification and biomarker development:

• Standardization of detection methods:

  • Establish standard operating procedures for IHC staining with validated antibodies

  • Develop quantitative scoring systems (H-score, Allred score, or digital image analysis)

  • Include reference standards in each batch to account for inter-assay variability

• Pre-analytical variables:

  • Document and control for sample collection methods

  • Standardize fixation protocols and times

  • Account for ischemia time which can affect fatty acid metabolism genes

  • Consider tissue-specific optimization of extraction protocols

• Selection of appropriate controls:

  • Include both positive and negative tissue controls in each run

  • Use internal controls (non-malignant cells within the same sample)

  • Consider gradient samples with known expression levels for quantitative calibration

• Interpretation frameworks:

  • Develop clear cutoff values for "high" versus "low" expression

  • The recent study suggests different prognostic implications of SLC27A2 expression in DLBCL versus AML, requiring disease-specific interpretation frameworks

  • Consider the relationship with other biomarkers in a multivariate context

• Clinical validation:

  • Test in independent patient cohorts

  • Evaluate reproducibility between different laboratories

  • Correlate with clinical outcomes and treatment response

• Technical considerations for quantitative methods:

  • For Western blot quantification: Use standard curves with recombinant protein

  • For IHC: Consider automated image analysis systems to reduce subjective interpretation

  • For qPCR: Select stable reference genes appropriate for the specific tissue context

These considerations are particularly important given the emerging role of SLC27A2 as a biomarker with opposing implications in different hematological malignancies .

What are promising research avenues for exploring SLC27A2's role at the intersection of metabolism and immunity?

The recent discovery of SLC27A2's involvement in immune cell regulation in hematological malignancies opens several exciting research directions:

• Metabolic reprogramming of immune cells:

  • Investigate how SLC27A2-mediated fatty acid transport affects T cell and macrophage function

  • Explore the metabolic dependencies of different immune cell subsets in relation to SLC27A2 activity

  • Study how SLC27A2 expression in tumor cells affects the metabolic competition within the tumor microenvironment

• Therapeutic targeting opportunities:

  • Develop selective inhibitors of SLC27A2 for potential application in AML, where high expression correlates with poorer outcomes

  • Explore strategies to upregulate SLC27A2 in DLBCL, where it appears to act as a tumor suppressor

  • Investigate combination approaches targeting both SLC27A2 and immune checkpoints

• Biomarker development:

  • Establish standardized SLC27A2 detection methods for clinical implementation

  • Investigate the predictive value of SLC27A2 expression for immunotherapy response

  • Develop multi-parameter biomarker panels incorporating SLC27A2 alongside immune markers

• Mechanistic studies:

  • Elucidate the molecular mechanisms connecting SLC27A2 to cell cycle regulation and apoptosis

  • Identify the signaling pathways mediating the interaction between SLC27A2 and immune cells

  • Explore potential non-metabolic functions of SLC27A2 in immune regulation

The differential association of SLC27A2 with immune cell infiltration in DLBCL (positive correlation with T cells, macrophages, and NK cells) versus AML (negative correlation with B cells, T cells, and macrophages) suggests complex, context-dependent mechanisms that warrant detailed investigation.

How can researchers optimize multi-parametric analysis incorporating SLC27A2 antibodies?

Advanced multi-parametric approaches can provide deeper insights into SLC27A2's role in complex biological systems:

• Multiplexed immunofluorescence:

  • Combine SLC27A2 antibodies (such as the Alexa Fluor 750-conjugated version ) with antibodies targeting:

    • Other metabolic enzymes (e.g., FASN, CPT1)

    • Immune cell markers (CD4, CD8, CD68)

    • Functional markers (Ki67, cleaved caspase-3)

  • Optimize antibody panels to minimize spectral overlap

  • Employ spectral unmixing algorithms for accurate signal separation

• Mass cytometry (CyTOF) approaches:

  • Develop metal-conjugated SLC27A2 antibodies for high-dimensional analysis

  • Create comprehensive panels examining metabolic, immune, and signaling pathways simultaneously

  • Apply unsupervised clustering algorithms to identify novel cell populations based on SLC27A2 expression

• Spatial transcriptomics integration:

  • Correlate protein-level SLC27A2 detection with spatial transcriptomic data

  • Map the relationship between SLC27A2 expression and immune niches within tumors

  • Develop computational approaches to integrate protein and RNA data

• Single-cell proteogenomic analysis:

  • Combine single-cell RNA sequencing with antibody-based protein detection

  • Correlate SLC27A2 protein levels with transcriptional programs at single-cell resolution

  • Identify cell state transitions associated with changes in SLC27A2 expression

These advanced approaches are particularly valuable for dissecting the complex role of SLC27A2 in heterogeneous systems like the tumor microenvironment, where recent research has revealed significant associations with immune cell infiltration patterns .

What experimental considerations are important when investigating SLC27A2 knockout or overexpression models?

When developing genetic models to study SLC27A2 function, researchers should consider several critical factors:

• Knockout model considerations:

  • Complete vs. conditional knockout strategies:

    • Complete knockout may affect development due to SLC27A2's role in metabolism

    • Tissue-specific or inducible systems (Cre-loxP, tetracycline-regulated) allow temporal control

  • Verification approaches:

    • Use validated SLC27A2 antibodies to confirm protein absence

    • Assess functional consequences (fatty acid uptake, metabolomics profiles)

    • Check for compensatory upregulation of other FATP family members

• Overexpression model design:

  • Expression system selection:

    • Constitutive vs. inducible promoters

    • Consider physiological expression levels to avoid artifacts

  • Tagging strategies:

    • C-terminal tags may be preferable as N-terminal modifications might affect localization

    • Verify tag does not interfere with function using fatty acid uptake assays

  • Controls:

    • Include empty vector and catalytically inactive mutant controls

• Phenotypic analysis:

  • Metabolic assessments:

    • Measure fatty acid uptake and oxidation rates

    • Perform lipidomics analysis

    • Assess mitochondrial function

  • Cell-specific phenotypes:

    • In hematological cells, examine proliferation, differentiation, and apoptosis

    • For immune cells, assess activation markers and cytokine production

    • Based on recent findings, monitor cell cycle distribution and apoptosis rates

• In vivo considerations:

  • For tumor models:

    • Assess both tumor cell-intrinsic effects and immune microenvironment changes

    • Monitor differential effects in DLBCL versus AML models, given the opposing associations observed

    • Consider combination with immune checkpoint modulators

These experimental considerations will help researchers develop robust models to further elucidate the dual roles of SLC27A2 in metabolism and immune regulation, particularly in the context of hematological malignancies.